Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity

Poulomi Sengupta, Sudipta Basu, Shivani Soni, Ambarish Pandey, Bhaskar Roy, Michael S. Oh, Kenneth T. Chin, Abhimanyu S. Paraskar, Sasmit Sarangi, Yamicia Connor, Venkata S. Sabbisetti, Jawahar Kopparam, Ashish Kulkarni, Katherine Muto, Chitra Amarasiriwardena, Innocent Jayawardene, Nicola Lupoli, Daniela M. Dinulescu, Joseph V. Bonventre, Raghunath A. MashelkarShiladitya Sengupta

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Nanoscale drug delivery vehicles have been harnessed extensively as carriers for cancer chemotherapeutics. However, traditional pharmaceutical approaches for nanoformulation have been a challenge with molecules that exhibit incompatible physicochemical properties, such as platinum-based chemotherapeutics. Here we propose a paradigm based on rational design of active molecules that facilitate supramolecular assembly in the nanoscale dimension. Using cisplatin as a template, we describe the synthesis of a unique platinum (II) tethered to a cholesterol backbone via a unique monocarboxylato and O→Pt coordination environment that facilitates nanoparticle assembly with a fixed ratio of phosphatidylcholine and 1,2-distearoyl-sn-glycero-3- phosphoethanolamine- N-[amino (polyethylene glycol)-2000]. The nanoparticles formed exhibit lower IC50 values compared with carboplatin or cisplatin in vitro, and are active in cisplatin-resistant conditions. Additionally, the nanoparticles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-RasLSL/+/Pten fl/fl ovarian cancer models with decreased systemic-and nephro-toxicity. Our results indicate that integrating rational drug design and supramolecular nanochemistry can emerge as a powerful strategy for drug development. Furthermore, given that platinum-based chemotherapeutics form the frontline therapy for a broad range of cancers, the increased efficacy and toxicity profile indicate the constructed nanostructure could translate into a nextgeneration platinum-based agent in the clinics.

Original languageEnglish (US)
Pages (from-to)11294-11299
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number28
DOIs
StatePublished - Jul 10 2012

Keywords

  • Chemotherapy
  • Nanomedicine

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Sengupta, P., Basu, S., Soni, S., Pandey, A., Roy, B., Oh, M. S., Chin, K. T., Paraskar, A. S., Sarangi, S., Connor, Y., Sabbisetti, V. S., Kopparam, J., Kulkarni, A., Muto, K., Amarasiriwardena, C., Jayawardene, I., Lupoli, N., Dinulescu, D. M., Bonventre, J. V., ... Sengupta, S. (2012). Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 109(28), 11294-11299. https://doi.org/10.1073/pnas.1203129109